Arcturus: Orphan Drug Designation for ARCT-032, for Treatment of Cystic Fibrosis

 First cystic fibrosis patient in Phase 1b study successfully completed two administrations of ARCT-032

On track to share interim Phase 1b data in H1 2024

https://www.biospace.com/article/releases/arcturus-therapeutics-receives-orphan-drug-designation-from-the-u-s-fda-for-arct-032-for-the-treatment-of-cystic-fibrosis/